Description
Aromasine or Aromed or Exemestane is indicated for the adjuvant treatment of invasive breast cancer at an early stage expressing estrogen receptors, in postmenopausal women, following an initial adjuvant treatment lasting 2 to 3 years by tamoxifen. Aromasine is indicated for the treatment of breast cancer at an advanced stage in postmenopausal women naturally or artificially after failure of treatment with antiestrogens.
In patients with early stage breast cancer, treatment with Aromasin should be continued until a total of five years of sequential adjuvant hormonal therapy (tamoxifen followed by Aromasin). It will be suspended if the tumor relapses.
Reviews
There are no reviews yet.